Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023		Sep. 30, 2024	Sep. 30, 2023
Income Statement [Abstract]
Revenues from sales of products	$ 9,104			$ 69,481	$ 157,618
Cost of sales	(76,761)			(110,523)	(70,229)
Gross profit	(67,657)			(41,042)	87,389
Research and development expenses	(122,410)	(1,693,205)		(249,966)	(1,828,970)
Selling and marketing expenses	(64,815)	(60,462)		(179,094)	(217,907)
General and administrative expenses	(1,294,913)	(1,103,257)		(2,844,967)	(3,481,408)
Operating loss	(1,549,795)	(2,856,924)		(3,315,069)	(5,440,896)
Financing income (expenses), net	(41,215)	10,579		(117,335)	43,666
Other income, net (Note 5(1))	247,808			353,033	12,294
Changes in fair value of an investment in an associate measured under the fair value option (Notes 3)	(970,505)	(189,683)		(856,836)	(87,576)
Net loss	(2,313,707)	(3,036,028)		(3,936,207)	(5,472,512)
Less: net loss attributable to non-controlling interests	50,497	670,432		115,985	683,733
Net loss attributable to the Company’s stockholders’ equity	$ (2,263,210)	$ (2,365,596)		$ (3,820,222)	$ (4,788,779)
Loss per share (basic)	$ (0.39)	$ (1.78)		$ (0.94)	$ (4.69)
Loss per share (diluted)	$ (0.39)	$ (1.78)		$ (0.94)	$ (4.69)
Weighted average number of shares outstanding, basic	5,820,287	1,331,070	[1]	4,069,690	1,020,339	[1]
Weighted average number of shares outstanding, diluted	5,820,287	1,331,070	[1]	4,069,690	1,020,339	[1]

[1] Adjusted to reflect one (1) for seven (7) reverse stock split in October 2023 (see note 1B).